LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
LifeMD (Nasdaq: LFMD) announced a lower cash-pay price for GLP-1 medications Wegovy and Ozempic as part of its collaboration with Novo Nordisk. LifeMD will offer the 0.25 mg and 0.5 mg doses at $199 per month for two fills for new patients, which the company describes as the lowest cash-pay pricing nationwide.
The drugs are offered through the LifeMD Weight Management Program, which includes virtual consultations, diagnostic testing, secure messaging, and lifestyle education. LifeMD cited a strategic shift from compounded GLP-1s to direct manufacturer partnerships to align with regulatory and reimbursement trends and to scale virtual obesity and metabolic care.
LifeMD (Nasdaq: LFMD) ha annunciato un prezzo cash-pay più basso per i farmaci GLP-1 Wegovy e Ozempic nell'ambito della sua collaborazione con Novo Nordisk. LifeMD offrirà le dosi da 0,25 mg e 0,5 mg a 199 dollari al mese per due cicli di trattamento per i nuovi pazienti, che l'azienda descrive come il prezzo cash-pay più basso a livello nazionale.
I farmaci sono offerti tramite il LifeMD Weight Management Program, che comprende consultazioni virtuali, test diagnostici, messaggistica sicura e istruzione sullo stile di vita. LifeMD ha citato uno shift strategico dai GLP-1 composti ai partenariati diretti con i produttori per allinearsi alle tendenze normative e di rimborso e per scalare la cura virtuale per obesità e metabolismo.
LifeMD (Nasdaq: LFMD) anunció un precio de pago en efectivo más bajo para los medicamentos GLP-1 Wegovy y Ozempic como parte de su colaboración con Novo Nordisk. LifeMD ofrecerá las dosis de 0,25 mg y 0,5 mg a 199 dólares al mes por dos rellenos para pacientes nuevos, que la empresa describe como el precio de pago en efectivo más bajo a nivel nacional.
Los medicamentos se ofrecen a través del programa LifeMD Weight Management Program (Programa de Manejo de Peso LifeMD), que incluye consultas virtuales, pruebas diagnósticas, mensajería segura y educación sobre el estilo de vida. LifeMD citó un cambio estratégico de GLP-1 compuestos a asociaciones directas con el fabricante para alinearse con las tendencias regulatorias y de reembolso y para escalar la atención virtual de obesidad y metabolismo.
LifeMD (나스닥: LFMD)는 Novo Nordisk와의 협력의 일환으로 GLP-1 약물 Wegovy 및 Ozempic의 현금 가격을 인하했다고 발표했습니다. LifeMD는 새로운 환자에 대해 두 차례 처방에 대해 0.25 mg 및 0.5 mg 용량을 월 199달러에 제공하며, 이는 회사가 전국 최저 현금가라고 설명합니다.
약물은 가상 상담, 진단 검사, 안전한 메시지 전송 및 생활 방식 교육을 포함하는 LifeMD 체중 관리 프로그램을 통해 제공됩니다. LifeMD는 규제 및 재보험 동향에 맞추고 가상 비만 및 대사 치료를 확장하기 위해 GLP-1의 혼합 제형에서 제조사 직접 파트너십으로의 전략적 전환을 지적했습니다.
LifeMD (Nasdaq : LFMD) a annoncé un prix en espèces plus bas pour les médicaments GLP-1 Wegovy et Ozempic dans le cadre de sa collaboration avec Novo Nordisk. LifeMD proposera les doses de 0,25 mg et 0,5 mg à 199 dollars par mois pour deux renouvellements pour les nouveaux patients, que l'entreprise décrit comme le prix cash-pay le plus bas au niveau national.
Les médicaments sont proposés via le LifeMD Weight Management Program (Programme de gestion du poids LifeMD), qui comprend des consultations virtuelles, des tests diagnostiques, des messages sécurisés et une éducation au mode de vie. LifeMD a évoqué un changement stratégique des GLP-1 composés vers des partenariats directs avec les fabricants afin de s'aligner sur les tendances réglementaires et de remboursement et de faire évoluer les soins virtuels de l'obésité et du métabolisme.
LifeMD (Nasdaq: LFMD) kündigte im Rahmen seiner Zusammenarbeit mit Novo Nordisk einen niedrigeren Barpreis für GLP-1-Medikamente Wegovy und Ozempic an. LifeMD wird die 0,25 mg- und 0,5 mg-Dosen zu je 199 US-Dollar pro Monat für zwei Nachfüllungen bei neuen Patienten anbieten, was das Unternehmen als niedrigsten Barpreis landesweit bezeichnet.
Die Medikamente werden über das LifeMD Weight Management Program angeboten, das virtuelle Beratungen, diagnostische Tests, sichere Nachrichtenübermittlung und Lifestyle-Schulung umfasst. LifeMD verwies auf eine strategische Abkehr von gemischten GLP-1s zugunsten direkter Partnerschaften mit Herstellern, um sich an regulatorische und Erstattungstrends anzupassen und die virtuelle Obesität- und Stoffwechselversorgung zu skalieren.
LifeMD (ناسداك: LFMD) أعلنت عن سعر نقدي أدنى لأدوية GLP-1 Wegovy و Ozempic كجزء من تعاونها مع Novo Nordisk. ستقدم LifeMD جرعات 0.25 ملغ و0.5 ملغ بسعر 199 دولارًا في الشهر لمدة تعبئتين للمرضى الجدد، والتي توصفها الشركة بأنها أقل سعر نقدي على مستوى البلاد.
يتم تقديم الأدوية من خلال برنامج LifeMD لإدارة الوزن، والذي يتضمن استشارات افتراضية، اختبارات تشخيصية، رسائل آمنة، وتثقيف حول أسلوب الحياة. أشارت LifeMD إلى تحوّل استراتيجي من GLP-1 المركبة إلى شراكات مباشرة مع الشركات المصنعة للتماشي مع اتجاهات التنظيم والتعويض وتوسيع الرعاية الافتراضية للسمنة والتمثيل الغذائي.
- 0.25 mg and 0.5 mg doses priced at $199/month for two fills
- Positioned as the lowest cash-pay pricing nationwide for Wegovy and Ozempic
- Weight Management Program includes virtual consults, diagnostics, messaging
- Shift from compounded GLP-1s to direct manufacturer partnerships for scalability
- Promotional price limited to two fills for new patients
- Offer covers only 0.25 mg and 0.5 mg dose strengths (limited dose range)
Insights
LifeMD cuts cash-pay prices for Wegovy and Ozempic to expand access via a Novo Nordisk collaboration.
LifeMD will offer the 0.25 mg and 0.5 mg doses of Wegovy® and Ozempic® at
Dependencies and risks center on continued supplier terms with Novo Nordisk, the operational capacity of LifeMD’s virtual platform to onboard increased patient volume, and adherence to emerging regulatory and reimbursement frameworks referenced in the announcement dated
Watch for near-term indicators such as reported fill volumes for the two promotional fills, any public statements from manufacturing partners altering terms, and program guidance in upcoming company disclosures over the next
LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality care
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy® and Ozempic®, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 mg and 0.5 mg doses at
These medications are available through the LifeMD Weight Management Program, which provides comprehensive support including virtual consultations with LifeMD’s dedicated clinical team, access to diagnostic testing, secure messaging through a personalized patient portal, and educational resources on diet and lifestyle changes that are important for sustained weight loss and metabolic health.
This update follows recent national efforts to improve affordability and access to GLP-1 therapies, including initiatives led by the White House and leading pharmaceutical manufacturers such as Novo Nordisk and Eli Lilly. As these developments continue to shape the market, LifeMD’s infrastructure, partnerships, and virtual care model position the company as a key player in supporting patients seeking clinically guided weight-loss care.
"We are proud to continue offering the most competitive cash-pay pricing for GLP-1 therapies in America," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Our goal remains the same: to maximize access to safe, FDA-approved medications through a frictionless virtual care experience that delivers long-term and sustainable weight loss and health benefits for our patients.”
LifeMD’s shift from compounded GLP-1s to direct partnerships with leading pharmaceutical manufacturers is central to its long-term growth strategy, reinforcing its commitment to emerging regulatory and reimbursement frameworks and to meeting rising demand for authentic obesity and metabolic care medications.
"These policy shifts not only validate our strategic direction but also demonstrate our alignment with both market needs and the future of healthcare," added Anthony Puopolo, M.D., President, LifeMD Affiliated P.C.s. "As demand for obesity and metabolic care continues to rise, LifeMD is exceptionally well positioned to deliver high-quality, affordable treatment options through a scalable, integrated virtual care platform."
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to expand access to high-quality, affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com
FAQ
What price will LifeMD (LFMD) charge for Wegovy and Ozempic starting Nov 17, 2025?
Which Wegovy and Ozempic dose strengths are included in LifeMD's $199 offer (LFMD)?
How can patients access the LifeMD (LFMD) GLP-1 pricing and services?
Is LifeMD's $199 GLP-1 price available to existing patients or only new patients (LFMD)?
Why is LifeMD (LFMD) shifting from compounded GLP-1s to manufacturer partnerships?
